Haas Named to Ligand Pharmaceuticals Board of Directors
30 June 2022 - - US-based biopharmaceutical company Ligand Pharmaceuticals Inc. (NASDAQ: LGND) has appointed Jason Haas to its board of directors, the company said.

Haas brings more than 30 years of healthcare investment banking and corporate finance experience to Ligand.

Haas is currently the CFO of Syros Pharmaceuticals, a NASDAQ listed biotech company focused on developing oncology therapeutics.

Prior to Syros, Haas spent over 25 years in healthcare investment banking where he executed many strategic transactions and supported companies through equity and debt financings, mergers and acquisitions, divestures, and spin-offs.

Haas served as Co-Head of Americas Healthcare Banking at Barclays, Head of Healthcare Investment Banking, Americas at Deutsche Bank and Managing director of Healthcare Investment Banking at Goldman Sachs.

Haas holds an M.B.A. in Finance from Columbia Business School and an A.B. in International Relations and Economics from Colgate University.

Ligand is a revenue-generating biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines.